NATCOPHARM

Natco Pharma Share Price

₹1,357.60 -17.15 (-1.25%)

25 Nov, 2024 02:35

SIP TrendupStart SIP in NATCOPHARM

Start SIP

Performance

  • Low
  • ₹1,353
  • High
  • ₹1,386
  • 52 Week Low
  • ₹752
  • 52 Week High
  • ₹1,639
  • Open Price₹1,380
  • Previous Close₹1,375
  • Volume361,884

Investment Returns

  • Over 1 Month + 2.83%
  • Over 3 Month -12.87%
  • Over 6 Month + 32.44%
  • Over 1 Year + 72.01%
SIP Lightning

Smart Investing Starts Here Start SIP with Natco Pharma for Steady Growth!

Invest Now

Natco Pharma Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 12.5
  • PEG Ratio
  • 0.2
  • Market Cap Cr
  • 24,316
  • P/B Ratio
  • 4.2
  • Average True Range
  • 43.71
  • EPS
  • 108.58
  • Dividend Yield
  • 0.3
  • MACD Signal
  • -8.34
  • RSI
  • 43.55
  • MFI
  • 55.88

Natco Pharma Financials

Natco Pharma Technicals

EMA & SMA

Current Price
₹1,357.60
-17.15 (-1.25%)
pointer
  • stock-down_img
  • Bullish Moving Average 4
  • stock-up_img
  • Bearish Moving Average 12
  • 20 Day
  • ₹1,383.81
  • 50 Day
  • ₹1,396.45
  • 100 Day
  • ₹1,355.12
  • 200 Day
  • ₹1,232.33

Resistance and Support

1365.68 Pivot Speed
  • R3 1,411.67
  • R2 1,399.03
  • R1 1,378.32
  • S1 1,344.97
  • S2 1,332.33
  • S3 1,311.62

What's your outlook on Natco Pharma?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

NATCO Pharma Ltd. is a leading Indian pharmaceutical company specializing in generic and specialty medicines, including oncology, cardiology, and central nervous system therapies. It serves global markets with a focus on affordable and high-quality healthcare solutions.

Natco Pharma has an operating revenue of Rs. 4,560.60 Cr. on a trailing 12-month basis. An annual revenue growth of 47% is outstanding, Pre-tax margin of 42% is great, ROE of 23% is exceptional. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading below to its 50DMA and around 14% up from its 200DMA. It needs to take out the 50DMA levels and stay above it to make any further meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 90 which is a GREAT score indicating consistency in earnings, a RS Rating of 72 which is FAIR indicating the recent price performance, Buyer Demand at B- which is evident from recent demand for the stock, Group Rank of 40 indicates it belongs to a strong industry group of Medical-Diversified and a Master Score of B is close to being the best. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock is lagging behind in some of the technical parameters, but great earnings make it a stock to examine in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Natco Pharma Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-11-12 Quarterly Results & Interim Dividend
2024-08-12 Quarterly Results & Interim Dividend
2024-05-27 Audited Results
2024-02-14 Quarterly Results & Interim Dividend
2023-11-14 Quarterly Results & Interim Dividend
Date Purpose Remarks
2024-11-27 INTERIM Rs.1.50 per share(75%)Second Interim Dividend (RD & XD dates revised)
2024-08-23 INTERIM Rs.3.00 per share(150%)Interim Dividend
2024-02-26 INTERIM Rs.1.25 per share(62.5%)Third Interim Dividend
2023-11-24 INTERIM Rs.1.25 per share(62.5%)Second Interim Dividend
2023-08-22 INTERIM Rs.7.00 per share(350%)Interim Dividend

Natco Pharma F&O

Natco Pharma Shareholding Pattern

49.62%
2.37%
4.23%
17.51%
0%
22.6%
3.67%

About Natco Pharma

Natco Pharma Ltd. is leading pharmaceutical company in India, specializing in production of generic medicines, bulk drugs, & specialty pharmaceuticals. Founded in 1981, Natco has established itself as key player in global pharmaceutical industry, with strong focus on oncology, cardiology, & gastroenterology segments. company operates state of the art manufacturing facilities that comply with global regulatory standards, ensuring production of high quality medicines. Natco Pharma is known for its innovation, particularly in development of affordable generic versions of high cost drugs, which has made it preferred partner for healthcare providers worldwide.

NATCO Pharma Limited (NATCO) is pharmaceutical firm that focuses on research & development & is vertically integrated. Its core competencies include creating, producing, & selling complicated pharmaceuticals for specific therapeutic areas. NATCO is now present in three business categories of contract manufacturing business, active pharmaceutical ingredients (APIs), & final dosage formulations (FDF).
 

View More
  • NSE Symbol
  • NATCOPHARM
  • BSE Symbol
  • 524816
  • ISIN
  • INE987B01026

Similar Stocks to Natco Pharma

Natco Pharma FAQs

Natco Pharma share price is ₹1,357 As on 25 November, 2024 | 02:21

The Market Cap of Natco Pharma is ₹24316 Cr As on 25 November, 2024 | 02:21

The P/E ratio of Natco Pharma is 12.5 As on 25 November, 2024 | 02:21

The PB ratio of Natco Pharma is 4.2 As on 25 November, 2024 | 02:21

Evaluate company's performance in pharmaceutical industry & its product pipeline before investing
 

Key metrics include revenue growth, product approvals, & profit margins.

Open Demat account with 5 Paisa Capital & post doing KYC & active account search for Natco Pharma share, you can then put order as you prefer.

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91
 
footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23